Key Neuromuscular Blocking Drugs Market Players:
- Merck & Co., Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Fresenius Kabi AG
- Pfizer Inc.
- Hikma Pharmaceuticals
- Mylan/Viatris Inc.
- Aspen Pharmacare
- Sandoz (a Novartis division)
- Bharat Serums and Vaccines Ltd.
- Nichi-Iko Pharmaceutical Co., Ltd.
- Yungjin Pharm Co., Ltd.
- Troikaa Pharmaceuticals Ltd.
- Gland Pharma Ltd.
- Piramal Pharma Solutions
- Hameln Pharma GmbH
- B. Braun Melsungen AG
- Orion Corporation
- TTY Biopharm Company Limited
- Aurobindo Pharma
- Malaysian Genomics Resource Centre
- CSL Limited
The neuromuscular blocking drugs market is dominated by Merck, Fresenius Kabi, and Pfizer based on their worldwide hospital networks and diversified NMBD portfolios. Players such as Hikma, Viatris, and Bharat Serums compete with others based on their portfolio via price-effective injectables. Strategic activities involve hospital group alliances, contract manufacturing, and filing for newer NMBD formulations with regulatory bodies. Japan, India, and South Korea players are capitalizing on local demand and cost competitiveness. Continuous and sustained R&D in short-acting and safer NMBDs keeps innovation for long-term competitiveness.
Below is the list of some prominent players operating in the market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of neuromuscular blocking drugs is evaluated at USD 4.3 billion.
The neuromuscular blocking drugs market size was valued at USD 4.3 billion in 2025 and is projected to reach USD 7.5 billion by the end of 2035, rising at a CAGR of 5.8% during the forecast period, i.e., 2026-2035.
North America neuromuscular blocking drugs market is expected to maintain the highest regional share by 2035, with about 36.9% of total revenue at a CAGR of 6.1% due to large volumes of surgical procedures, strong healthcare infrastructure, and government-supported reimbursements.
The major players in the market are Merck & Co., Inc., Fresenius Kabi AG, Pfizer Inc., Hikma Pharmaceuticals, Mylan/Viatris Inc., Aspen Pharmacare, Sandoz (a Novartis division), Bharat Serums and Vaccines Ltd., Nichi-Iko Pharmaceutical Co., Ltd., Yungjin Pharm Co., Ltd., Troikaa Pharmaceuticals Ltd., Gland Pharma Ltd., Piramal Pharma Solutions, Hameln Pharma GmbH, B. Braun Melsungen AG, Orion Corporation, TTY Biopharm Company Limited, Aurobindo Pharma, Malaysian Genomics Resource Centre, CSL Limited.
